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Summary
The goal of our work was the design of DNA-damag-
ing agents that disrupt both DNA repair and signaling
pathways in prostate tumor cells. A DNA alkylator
(N,N-bis-2-chloroethyl aniline) was linked to a steroid
ligand (17-hyroxy-estra-4(5),9(10)-3-one) to produce a
complex molecule (11-dichloro) that forms DNA ad-
ducts that bind the androgen receptor (AR). We spec-
ulated that DNA adducts in an AR-DNA adduct com-
plex would be camouflaged from DNA repair proteins
that would otherwise remove the adducts in prostate
cancer cells. Furthermore, transcription dependent
on the AR would be antagonized by AR redistribution
to sites distant from AR-driven promoters. The anti-
cancer potential of 11-dichloro was demonstrated
against prostate cancer cells in vitro and in vivo. 11-
dichloro induces a unique pattern of gene disruption,
induces apoptosis in apoptosis-resistant cells, and
shows promising anticancer activity in animals.
Introduction
Cytotoxic agents that act by covalent modification of
DNA were the first modern anticancer chemotherapeu-
tics and remain major components of combination che-
motherapy regimens [1, 2]. In combination with drugs
that act by other mechanisms, alkylating antitumor drugs
have produced impressive and even curative responses
in the treatment of some cancers (e.g., cisplatin in tes-
ticular cancer) [3]. Frequently, however, tumors are
found to have inherent resistance to these compounds
or to develop resistance during the course of treatment.
The rapid evolution of resistance makes it imperative
to develop new agents that can defeat the molecular
barriers responsible for clinical failure.
The strategy of combining several agents that can
increase the vulnerability of certain cancers to alkylat-
ing drugs is one approach to overcoming resistance.
Sometimes, however, drug-drug interactions or over-
lapping side-effect profiles make multidrug regimens
problematic.
Another strategy is the design of alkylating compounds
with novel mechanisms that disrupt multiple biochemi-
cal pathways responsible for tumor growth and sur-
vival. We report the design, synthesis, and biological
activities of a multifunctional compound based on an
original concept that sought to incorporate several*Correspondence: jessig@mit.edu (J.M.E.); rgcroy@mit.edu (R.G.C.)mechanisms of action into a single anticancer agent.
Our idea was to produce a compound that could form
covalent DNA adducts that have high affinity for a pro-
tein essential for the growth and survival of tumor cells.
Protein-adduct complexes formed in these cells would
not only camouflage the DNA adduct, making it difficult
to repair, but also prevent the protein from performing
its role in cell growth and/or survival. Figure 1A il-
lustrates these mechanisms showing alternative fates
of DNA adducts formed by the reactive “warhead” por-
tion. On the left, exposed DNA adducts that are not
bound to proteins through the protein recognition (or
“ligand”) domain can be detected and efficiently ex-
cised by repair enzymes, limiting potential genotoxic
effects. On the right, however, the “ligand domain”
(e.g., a steroid) forms a complex with its cognate pro-
tein in target cells, camouflaging adducts and interfer-
ing with both the repair process and the normal biologi-
cal function of the protein bound to the adduct. Cells
that express proteins that bind to the ligand domain will
be more vulnerable to the toxic effects of the syn-
thetic toxins.
The concept that one could use a custom-designed
DNA-damaging agent to hijack a nuclear transcription
factor required for cancer-cell growth was introduced
by the design and synthesis of compounds that pro-
duce DNA adducts to which the estrogen receptor (ER)
binds with high affinity [4–6]. Breast cancer cells that
express high levels of the ER show greater sensitivity
toward these compounds. The current paper describes
the design, chemical synthesis, and biological activities
of compounds that have been designed to form DNA
adducts that bind to the androgen receptor (AR), a tran-
scription factor expressed at high levels in many pros-
tate cancers [7]. AR expression is found in primary
prostate cancer and is frequently observed in both hor-
mone-sensitive and hormone-refractory forms of the
disease [8]. There is currently no effective long-term
treatment for the advanced hormone-refractory stage
of the disease. Mutations in the AR, along with aberrant
expression of coactivator proteins, can allow transcrip-
tional activation in response to antiandrogens and en-
dogenous hormones, leading to cancer progression
and therapeutic resistance [9, 10]. The premise of se-
questering the AR at sites of DNA adducts was that
repair of the genetic damage that is camouflaged in the
receptor-adduct complex would be impeded, as would
the function (or functions) of the AR responsible for tu-
mor growth.
We report the synthesis and activities of a bifunc-
tional compound composed of N,N-bis-(2-chloroethyl)-
aniline linked to an 11β-substituted estra4(5),9(10)-3-
one. This new compound, 11β-dichloro (Figure 1B), is
capable of producing DNA adducts that interact with
the AR. To investigate the mechanism of action of this
compound, we prepared an unreactive analog that
could not form DNA adducts (11β-dimethoxy) (Figure
1B). Investigation of the biological responses of LNCaP
cells to our 11β compounds revealed biochemical changes
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780Figure 1. Scheme Illustrating the Mechanism
of Selective Toxicity by Compounds that
Form DNA Adducts that Attract Proteins in
Cancer Cells
(A) 11β-dichloro was designed to have the
ability to covalently modify DNA and still re-
tain the ability to bind the protein with which
the protein recognition domain was de-
signed to interact. In noncancer cells, which
don’t express the protein of interest at high
levels, adducts are repaired by DNA repair
enzymes. In cancer cells, in which the pro-
tein of interest is overexpressed, binding of
the protein to adducts blocks adduct repair
and prevents the protein of interest from car-
rying out its normal function in the cell.
(B) Structure of 11β compounds. 11β-dichl-
oro forms DNA adducts with affinity for the
AR and PR. 11β-dimethoxy does not form
DNA adducts but does have affinity for the
AR and PR.that are of interest with regard to the antitumor effects c
awe observed in animal models.
t
dResults
p
ASynthesis of Bifunctional 11-Substituted
Estradien-3-One Compounds c
tThe design of the androgen ligand portion of the 11β
compounds is based on the reported antiandrogenic w
nactivity of molecules containing 11β-substituted 17β-
hydroxy-estra-4(5),9(11)-3-one [11]. The general synthetic b
tstrategy for linking the 11β-substituted estradien-3-one
to N,N-bis-(2-chloroethylaminophenyl)-propylamine is a
shown in Figure 2. Epoxide 1 was prepared by epoxida-
tion of the known compound 3,3-ethylenedioxy-17β- 1
whydroxyestra-5(10),9(11)-diene by a published pro-
cedure [12]. The alkyl chain was then introduced at the t
K11β position by conjugate opening of the allylic epoxide
(1) by the Grignard reagent prepared from the alkyl bro- c
amide in the presence of copper(I) [13]. Steroid alcohol
(2) was converted to the bromide and allowed to react d
5with a protected ethanolamine to give the alcohol (3),
which was converted to a carbonate intermediate with w
1p-nitrophenyl chloroformate. The carbonate was then 1β-dimethoxy analog in order to determine the ability
Figure 2. Synthetic Scheme for Synthesis of
the 11β-dichloro Compound
(a) tBDMSO(CH2)6MgBr, CuBr•Me2S, THF,
−20°C; (b) tBuNH4F, THF, room temperature
(rt); (c) CH3SO2Cl, DIEA, THF, 0°C; (d) LiBr,
DMF, 45°C; (e) Ph2P(O)NH(CH2)2OtBDMS,
Bu4NBr, NaH, benzene, 65°C; (f) tBuNH4F, THF,
rt; (g) p-nitrophenylchloroformate, DIEA, TFH,
rt; (h) 4-(N,N-bis-2-chloroethylaminophenyl)-
proplyamine, DIEA, THF, 75°C; (i) HCl, THF, rt.oupled to N,N-bis-(2-chloroethylaminophenyl)-propyl-
mine, and the final product, 11β-dichloro (4), was ob-
ained by removal of protecting groups under acidic con-
itions. Details of some of these procedures have been
ublished [5] and are contained in Supplemental Data.
n unreactive analog of 11β-dichloro, in which the two
hlorine atoms of the 2-chloroethyl groups were substi-
uted by methoxy groups (11β-dimethoxy) (Figure 1B),
as prepared by reflux of 4-(N,N-bis-2-chloroethylami-
ophenyl)-propylamine with NaOCH3 producing 4-(N,N-
is-2-methoxyethylaminophenyl)-propylamine, which was
hen substituted for its chloro analog in the synthesis
s described for 11β-dichloro.
1-Dichloro Forms DNA Adducts that Interact
ith the Androgen Receptor and
he Progesterone Receptor
ey to the biological activities of our bifunctional mole-
ules is their ability to covalently modify DNA, forming
dducts that bind to the androgen receptor (AR). A ra-
iolabeled, self-complementary deoxyoligonucleotide,
#[32P]-d(ATTATTGGCCAATAAT)-3#, was incubated either
ith the 11β-dichloro compound or with the unreactive
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tion of modified bases as well as the extent of modifica-
tion were determined by piperidine cleavage followed
by gel electrophoresis [5]. As expected, the 11β-dichloro
formed covalent products that resulted in fragmenta-
tion of the deoxyoligonucleotide at either guanine resi-
due upon incubation with piperidine (data not shown).
Approximately 75% of the oligonucleotide treated for 4
hr with 125 uM 11β-dichloro was found to be piperidine
labile. Under the same conditions, the 11β-dimethoxy
did not produce any piperidine-labile sites.
The relative affinities of the 11β compounds for the
AR and the progesterone receptor (PR) were deter-
mined by competitive binding assays. The results of
these assays are shown in Table 1. The 11β-dichloro
compound was found to have a relative binding affinity
(RBA) of approximately 11% for the AR in whole-cell
LNCaP extracts when compared with the synthetic an-
drogen [3H]-R1881. Because the affinity of R1881 for
the LNCaP AR is about twice that of a natural ligand,
dihydrotestosterone (DHT) [14], the RBA of 11% implies
that the affinity of 11β-dichloro is approximately 20%
that of a natural ligand. Comparing 11β-dichloro with
[3H]-progesterone, we found that 11β-dichloro had a
much lower affinity for the PR, with an RBA of 4%. Sub-
stitution of chlorine atoms by methoxy groups in the
11β-dimethoxy analog did not influence receptor bind-
ing. The RBAs of the 11β-dimethoxy compound for the
AR and PR were similar to those of 11β-dichloro (Ta-
ble 1).
We also estimated the RBA for the AR of 11β-DNA
adducts formed by incubation of the self-complemen-
tary deoxyoligonucleotide 5#-d(ATTATTGGCCAATAAT)-
3# with the 11β-dichloro compound. Addition of 11β-
modified DNAs—but not unmodified DNAs—resulted in
decreased amounts of [3H]-R1881 bound to the AR in
cell-free extracts from LNCaP cells. Based on the molar
concentration of DNA adducts added, we estimate an
RBA of 0.2% for the covalently linked ligand when com-
pared to R1881 (Table 1).
11 Compounds Induce Growth Arrest
and Apoptosis in LNCaP Cells
The biological effects of the 11β-dichloro and 11β-
dimethoxy compounds were examined in AR-positive
LNCaP prostate cancer cells in culture. LNCaP cells ex-
posed to 11β-dichloro at concentrations >5 M un-
derwent rapid morphological changes associated with
apoptosis. Figure 3 shows the physical appearance of
LNCaP cells left untreated (Figure 3A), after a 6 hr expo-
sure to 20 M chlorambucil (Figure 3B), after 6 hr treat-
ment with 10 M 11β-dichloro (Figure 3C), and after 6
hr treatment with 10 M 11β-dimethoxy (Figure 3D). WeTable 1. Relative Binding Affinities of 11β-Compounds and 11β-DNA Adducts for the Androgen Receptor and Progesterone Receptor
Receptor 11β-Dichloro 11β-Dimethoxy 11β-Modified DNA
AR 11.3% (9.7–13.2) 18.1% (15.5–21.1) 0.22% (0.12–0.43)
PR 4.2% (3.5–4.8) 3.6% (3.1–4.3) 0.04% (0.02–0.08)
RBA: relative binding affinity of test compound compared with R1881 (RBA = 100%) for AR or progesterone (RBA = 100%) for PR as
determined by competitive binding assay with [3H]-R1881 (AR) or [3H]-progesterone (PR); values in parentheses represent the 95% confidence
interval for calculated RBAs.cil were stained with the vital stain 7-amino-actinomy-
Figure 3. Images of LNCaP Cell Morphology and Cell-Cycle Analy-
sis of LNCaP Cells Treated with 11β Compounds
Top: LNCaP cells after 6 hr treatment with 11β compounds (10 M)
or the anticancer drug chlorambucil (20 M). Cells in exponential
growth phase were treated for 6 hr, fixed, and stained with Giemsa.
(A) Vehicle-treated LNCaP cells. (B) Cells exposed to chlorambucil
showed no effect on cellular shape. (C) Cells treated with 11β-dichloro
showed dramatic contraction and detachment. (D) Cells treated
with the unreactive 11β-dimethoxy showed slight contraction,
which was reversed by 24 hr (not shown). Bottom: cell-cycle analy-
sis of LNCaP cells treated with indicated compounds for 17 hr.selected chlorambucil for comparison because it con-
tains the identical N,N-bis-(2-chloroethyl)-aniline moi-
ety as does 11β-dichloro and would therefore be ex-
pected to modify covalently the same atoms in DNA
[15]. Despite their chemical similarities, treatment with
11β-dichloro resulted in striking cytoplasmic con-
traction and detachment from the culture dish within 6
hr, whereas treatment with chlorambucil did not. Treat-
ment of LNCaP cells with 11β-dimethoxy produced a
transient and less-dramatic change in cell morphology.
The cells remained attached to the surface of the cul-
ture dish and recovered to their pretreatment morphol-
ogy by 24 hr.
To determine whether an apoptotic program was ac-
tivated by 11β-dichloro, we examined the status of sev-
eral apoptotic markers in the treated cells. Annexin V
staining was used as an early marker of changes in
membrane phospholipids that are associated with cells
undergoing apoptosis [16]. LNCaP cells treated for vari-
ous lengths of time with 11β compounds or chlorambu-
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cin D (7-AAD) as well as a phycoerytherin-labeled c
antibody to Annexin V. Analysis of stained cells by flow e
cytometry revealed a progression of cells from those a
that were initially Annexin-positive to a population that t
stained with both Annexin and 7-AAD, indicating a loss c
of membrane integrity. These changes were not ob- i
served in LNCaP cells treated with either 11β-dimeth- c
oxy or chlorambucil (Figure 4A). Analysis of DNA iso- t
lated from treated cells revealed the internucleosomal d
fragmentation and laddering pattern of genomic DNA D
that is consistent with the activation of an apoptotic w
endonuclease [17] only in LNCaP cells treated with 11β- p
dichloro (Figure 4B). DNA that was isolated from cellst
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Figure 4. LNCaP Cells Undergo Apoptosis Upon Treatment with c
11β-dichloro t
(A) Annexin V staining of LNCaP cells after treatment for 15 hr with t
indicated compounds. Cells treated with >5 M 11β-dichloro e
showed evidence of increased Annexin V staining. w
(B) Agarose gel electrophoresis of DNA isolated from LNCaP cells e
after 24 hr exposure to chlorambucil (20 M), 11β-dichloro (10 M),
or 11β-dimethoxy (10 M). DNA fragmentation occurs in cells
ttreated with 11β-dichloro.
b(C) Western blot analysis of cellular extracts probed with antibodies
against full-length and cleaved PARP showed that treatment with a
11β-dichloro (10 M) led to cleavage of PARP within 9 hr. No cleav- m
age was seen in cells treated with either chlorambucil (20 M) or w
11β-dimethoxy (10 M). o
breated with 11β-dimethoxy or chlorambucil remained
t high molecular weight. Furthermore, cleavage of
oly-ADP ribose polymerase (PARP), another apoptotic
arker [18], was also seen in LNCaP cells treated with
1β-dichloro but not in cells treated with 11β-dimeth-
xy or chlorambucil (Figure 4C). These data indicate
hat 11β-dichloro is clearly effective in overcoming the
oadblocks in LNCaP cells that prevent the conven-
ional DNA damaging agent chlorambucil from initiat-
ng apoptosis.
Although it did not cause apoptosis, the unreactive
1β-dimethoxy compound did have an effect on cell
rowth. Analysis of the cell-cycle distribution of LNCaP
ells treated with 11β-dimethoxy indicated that the
ells arrested in the G1 phase of the cell cycle (Figure
D). Similar analyses revealed a sub-G1 apoptotic frac-
ion in LNCaP cells treated with 11β-dichloro (Figure
C), whereas cells treated with chlorambucil were pri-
arily blocked in S phase (Figure 3B).
The results described above led us to investigate the
xpression of the G1 cell-cycle checkpoint proteins,
pecifically the cyclin-dependent kinase (CDK) inhibi-
ors p21 and p27, to determine their involvement in the
rowth arrest and apoptotic responses of LNCaP cells
reated with the 11β compounds. Figure 5A shows the
evels of these two CDK inhibitors in LNCaP cells ex-
osed for up to 15 hr with 11β-dichloro, 11β-dimethoxy,
r chlorambucil. The levels of p21 were affected by all
hree compounds. Amounts of p21 initially decreased
n cells treated with either of the 11β compounds. This
nitial reduction was followed by either recovery of p21
rotein to a basal level in cells treated with 11β-dimeth-
xy (6–9 hr) or an increase by several fold in cells
reated by 11β-dichloro (15 hr). In response to chloram-
ucil, the amount of p21 showed a constant increase
hroughout the 15 hr period. Thus, p21 levels were in-
reased at 15 hr in cells treated with either compound
hat was capable of forming DNA adducts but not in
hose treated with the unreactive 11β-dimethoxy. The
xpression level of p27 was unchanged by treatment
ith chlorambucil. Both of the 11β compounds, how-
ver, increased the level of p27 expression.
Given that our compound design was based on the
ethering of two distinct chemical entities—a ligand
inding portion similar in structure to the PR and AR
ntagonist mifepristone (RU486) and a DNA-damaging
oiety similar to the nitrogen mustard chlorambucil—
e were interested in learning if the rapid changes we
bserved in the levels of the two CDK inhibitors could
e reproduced by treatment with RU486 alone or in
ombination with DNA damage caused by chlorambu-
il. Figure 5B clearly illustrates the need for the two
ntities to be linked. As previously determined, chlor-
mbucil increased expression levels of p21. However,
reatment with chlorambucil alone, RU486 alone, or a
ombination of the two did not affect the levels of p27
n cells during exposures up to 15 hr. In addition, cell-
ycle analysis of LNCaP cells treated with the combina-
ion of RU486 and chlorambucil did not reveal any evi-
ence of nuclear fragmentation (cells with a sub-G1
NA content) suggesting that—similar to treatment
ith chlorambucil alone—this combination was not ca-
able of inducing apoptosis (data not shown).
The levels of p27 can be regulated by the protein’s
Bifunctional DNA-Damaging Anticancer Compound
783Figure 5. Immunoblot Analysis of Cell-Cycle
Checkpoint Proteins in LNCaP Cells
(A) Levels of p21CIP1 and p27KIP1 in extracts
from LNCaP cells that were treated with
chlorambucil (20 M), 11β-dichloro (10 M),
or 11β-dimethoxy (10 M) for up to 15 hr.
(B) Levels of p21CIP1 and p27KIP1 in extracts
of LNCaP cells treated for 15 hr with chlor-
ambucil (10 M), RU486 (10 M), or both
(each at 10 M).
(C) Levels of Skp2 in extracts of LNCaP cells
treated under the same conditions as in (A).ubiquitin-dependent degradation through the ubiquitin
E3 ligase SCFSKP2 [19, 20]. Therefore, it was of interest
to probe the effects of 11β-dichloro and its dimethoxy
analog on the expression levels of Skp2, the F box pro-
tein component of the SCF ubiquitin ligase complex.
Figure 5C shows the effects of both compounds on
Skp2 levels in LNCaP cells treated for up to 15 hr. Treat-
ment with either of the 11β compounds resulted in de-
creased expression of Skp2. The decreases in Skp2 ex-
pression correlate well with the relative levels of
increase in the expression of p27 in LNCaP cells treated
with the 11β compounds. The reciprocal pattern of ex-
pression of these proteins shown in Figures 5A and 5C
is consistent with the view that Skp2 is directly involved
in the increased expression of p27 in LNCaP cells
treated with these compounds.
11-Dicholoro Inhibits Growth of LNCaP Cells
in a Mouse Xenograft Model of Human Cancer
The sensitivity of LNCaP cells in culture to 11β-dichloro
led us to investigate its antitumor activity against
LNCaP cells growing as xenografts in nude mice. Pre-
liminary toxicology studies in nontumor-bearing mice
found that a consecutive 5-day schedule of 30 mg/kg
was well tolerated by the animals as evidenced by mini-
mal weight loss and lack of elevated liver transaminase
levels (data not shown). Tumor-bearing animals were
treated on a schedule of seven consecutive weekly
5-day cycles with a daily dose of 30 mg/kg adminis-
tered by intraperitoneal injection. Control animals re-
ceived vehicle only. As shown in Figure 6, this regimen
resulted in a 90% inhibition of tumor growth when as-
sessed on the final day of the study (mean tumor vol-
ume [treated] versus mean tumor volume [control] on
day 45; p < 0.0001). During the 45-day period, the treat-
ment group experienced a mean weight loss of 9.7%
compared with the vehicle-treated group. These data
demonstrate that at tolerable doses, 11β-dichloro inhib-
its the growth of LNCaP prostate cancer cells in vivo. The
tumoristatic effect that we observed in this model may
be due to the relatively small initial size of the tumors
(5 mm diameter) at the initiation of treatment with 11β-
dichloro. We are investigating the responses of larger,
more established tumors to determine whether the cy-
totoxic responses observed in vitro occur in xenografts
resulting in the reduction in tumor size.apoptotic responses in LNCaP cells distinguish the
Figure 6. Response of LNCaP Androgen-Dependent Xenografts to
11β-Dichloro
Bars at bottom each represent five consecutive daily doses of 30
mg/kg. Triangles represent tumor volume in mice treated with 11β-
dichloro; squares represent tumor volume in control mice treated
with vehicle only. (Average tumor volume ± s.d.; n = 5)Discussion
In this report, we examined the effects of a new, ra-
tionally designed, multifunctional compound on the
growth of LNCaP prostate cancer cells in culture and
in a xenograft animal model. We programmed our com-
pound to produce DNA adducts that would be able to
form complexes with a protein that was aberrantly ex-
pressed in tumor cells. The new compound (11β-dichloro)
comprises a steroid moiety with high affinity for the
androgen receptor tethered to a reactive N,N-bis-
(2-chloroethyl)-aniline. We found that 11β-dichloro causes
increased expression of the cell-cycle checkpoint pro-
teins p27 and p21 along with the rapid induction of
apoptosis. Because 11β contains a DNA alkylator, one
could argue that the DNA damage response initiates
the observed cellular effects; we did not observe, how-
ever, upregulation of p27 or apoptosis with free chlor-
ambucil. Neither did we observe apoptosis with an un-
reactive 11β analog that induced p27 and growth arrest
at the G1 stage of the cell cycle. The checkpoint and
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There are examples in the literature of molecules in s
Dwhich steroid receptor ligands have been combined
with chemically reactive genotoxins [21–25]. In most r
cases, the steroid portion of such molecules is de-
signed to function as a delivery agent and the linker is i
tprogrammed to hydrolyze and release the active toxin
in target cells that express the cognate receptor. In i
acontrast, the linker in our compounds is designed to
possess chemical stability as well as to resist hydroly- f
asis by proteases and esterases. Our experiments dem-
onstrate that this manner of linking the two active g
cpharmacophores in 11β-dichloro resulted in cellular re-
sponses distinct from those of the independent com- L
ipounds.
The results reported here expand on earlier work in [
iwhich we prepared a group of compounds with the abil-
ity to form DNA adducts that can bind the estrogen re- e
gceptor and selectively kill ER-positive breast cancer
cells [4, 5]. Based on the structural similarity of the c
aAR to other steroid receptor proteins [26], we incorpo-
rated the molecular features and dimensions that u
cproved successful in the development of our initial ER
binding bifunctional compounds into the design of new i
pcompounds that have good affinity for the AR. Pre-
vious studies established the importance of an alkanyl d
pchain of at least six carbons for binding of modified
ligands to the ER. We based our attachment of a six- a
carbon alkyl chain at the 11β position of 17-hydroxy-
estra4(5),9(11)-3-one on the reported affinity of the anti- p
tprogestin drug RU486 for the AR [27]. The remaining
features of the new compound directed at prostate C
[cancer cells were adopted from our previous work [4].
Biophysical characterization of the new molecule found p
cthat it had good affinity for the AR of LNCaP cells com-
pared to the natural ligand dihydrotestosterone. The r
LNCaP cell line has a mutation at residue 877 of the AR
that alters its affinity for androgen agonists and antago- w
gnists [28, 29]. This mutation has been found in patients
with advanced, androgen-independent metastatic pros- t
ptate cancer [30]. It may be necessary to alter the ligand
portion of the 11β molecule to increase its affinity for m
Tother genetic variants of the AR that occur in prostate
malignancies. t
tThe 11β-dichloro compound formed reactive inter-
mediates that produced covalent adducts in DNA. The t
orelative affinity for the AR of these DNA-bound ligands
was lower than that of the unreacted 11β-dichloro com-
opound. This may be because unlike the free compound,
the 11β-modified DNA contains a variety of structures e
rthat may have different steric requirements for binding
to the AR. Additional investigations are required to de- r
itermine if a range of affinities for the AR exists for vari-
ous 11β-DNA adducts and their relevance to our in- d
ltended mechanisms of action.
Our studies explored the relationship between the c
mformation of DNA adducts and the ability of 11β-dichloro
to cause cell-cycle arrest and apoptosis. Through d
ichemical substitution, we prepared an unreactive ana-
log of 11β-dichloro that was incapable of forming DNA c
dadducts. We demonstrated that the unreactive analog
(11β-dimethoxy) was not able to induce apoptosis, al- f
othough it was able to block LNCaP cells in the G1hase of the cell cycle, at least temporarily. The results
ith the control unreactive derivative of 11β-dichloro
hed light on the mechanisms of action independent of
NA damage that contribute to the rapid and dramatic
esponse of LNCaP cells to 11β-dichloro.
Direct interaction of the 11β-dimethoxy with the AR
n the LNCaP cell line provides one possible explana-
ion for its ability to induce G1 cell-cycle arrest through
ncreased expression of p27, the CDK inhibitor that
cts to inhibit G1 cyclin/CDK complexes [31]. The ef-
ects of androgens on the proliferation of LNCaP cells
re well characterized. Low concentrations of andro-
ens such as DHT stimulate growth, whereas high con-
entrations are inhibitory [32, 33]. Treatment of growing
NCaP cells with 100 nM DHT has been shown to result
n accumulation of p27 and growth arrest within 24 hr
34]. In addition, p27 accumulation during androgen-
nduced growth arrest has been linked to decreased
xpression of the Skp2 subunit of the ubiquitin E3 li-
ase SCFSkp2 [20]. The direct binding of Skp2 to the
yclin kinase subunit CKS1 directs the ubiquitination
nd subsequent proteolysis of p27 [35, 36]. We have
ncovered a similar reciprocal relationship between de-
reased expression of Skp2 and accumulation of p27
n LNCaP cells treated with the 11β-dichloro com-
ound. In the case of 11β-dichloro, however, the cells
o not arrest in G1 but instead, rapidly undergo apo-
tosis. This latter property, of course, is of value in an
nticancer agent.
During the cell cycle, downregulation of the Skp2
rotein is mediated by its APCcdh1-mediated ubiquitina-
ion and destruction [37]. It has been reported that
dh1 can be activated by some forms of DNA damage
38]. This possibility suggests that 11β-dichloro may be
articularly effective in decreasing Skp2 expression be-
ause of its effect on both the AR and DNA-damage
esponse pathways that can control Skp2 expression.
The association of the AR with 11β-DNA adducts
ould be expected to antagonize the transcription of
enes from AR promoter sequences. Androgen abla-
ion as well as therapy with androgen antagonists that
revent AR-mediated gene expression are effective
eans to control prostate cancer in its early stages.
hese strategies fail, however, when mutations activate
he AR directly or result in its activation by former an-
agonists that stimulate cell growth. Sequestration of
he AR by 11β-DNA adducts would be expected to
vercome both of these resistance mechanisms.
We also observed the increased expression of an-
ther CDK inhibitor, p21, in LNCaP cells treated with
ither chlorambucil or 11β-dichloro but not with the un-
eactive 11β-dimethoxy analog. p21 plays an essential
ole in growth arrest after DNA damage [39]. Our find-
ngs suggest that p21 expression is modulated by DNA
amage produced by the reactive compounds, most
ikely through activation of the p53 pathway. LNCaP
ells express wild-type, functional p53 [40], which is a
ajor regulator of p21 transcription in response to DNA
amage [41]. There are several reports indicating that
ncreased expression of p21 protects prostate cancer
ells, as well as other cell types, against apoptosis in-
uced by a variety of anticancer agents [39, 42]. These
indings suggest significance to the different patterns
f p21 induction that we observed in LNCaP cells
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785treated with chlorambucil or 11β-dichloro. Although
chlorambucil produced a rapid increase in the level of
p21, the 11β-dichloro compound initially decreased
levels of p21 in LNCaP cells. Because the initial reduc-
tion of p21 levels also occurred with the unreactive 11β-
dimethoxy analog, other features of our compounds,
unrelated to DNA damage, are likely involved in this re-
sponse.
The capacity of p21 to halt cell-cycle progression
through inhibition of CDKs, as well as through its in-
teraction with the proliferating cell nuclear antigen
(PCNA), which stops DNA synthesis [43], provides an
explanation for the accumulation in S phase and the
survival of LNCaP cells after treatment with chlorambu-
cil. In contrast, we did not observe an increase in the
number of LNCaP cells in S phase during treatment
with 11β-dichloro. Early elimination and delayed in-
crease in the expression of p21 in cells treated with
11β-dichloro may disable a key checkpoint that nor-
mally arrests cells in S phase to allow for the repair of
DNA damage, thus sensitizing the cells to apoptosis.
Further investigation is required to identify the mecha-
A
nism (or mechanisms) underlying the initial reduction of
p21 in 11β-treated cells and the role this reduction
plays in the cytotoxic effects of our compounds.
The mustard class of anticancer agents includes the
first drugs used in modern chemotherapy as well as
many that are used daily in the clinic today. The de-
velopment of new DNA-damaging anticancer drugs,
however, has not been the subject of intense research
in recent years. Discovery of new anticancer drugs has
increasingly focused on targeting pathognomonic
changes in cancer cells. The objective of this work was
to create multifunctional compounds that combine the
modern “targeted” approach with the more traditional
methods that are directed against the broad target of
DNA replication, upon which tumor cells depend. Se-
lectivity and efficacy of these compounds may not de-
pend on absolute restriction of a single target in a ma-
lignant cell but, rather, from the decreased ability of
malignant cells, as compared with their normal counter-
parts, to cope with perturbations in multiple pathways.
Significance
We report the induction of growth inhibition, apopto-
sis, and antitumor activity by a unique bifunctional
conjugate that comprises a DNA alkylator and a ste-
roid ligand for the androgen receptor. The new mole-
cule (11-dichloro) was designed to target several
biochemical pathways upon which prostate tumor
cells depend for growth and resistance to existing an-
ticancer drugs. Unlike previous steroid-alkylator com-
binations, the conjugate molecule has a chemically
stabile linkage that confers the ability to form cova-
lent DNA adducts that have affinity for the androgen
receptor (AR). We propose that creation of AR-DNA
adduct complexes interferes with DNA repair and dis-
rupts AR-mediated transcription and signaling. Evi-
dence of a unique mechanism of action was obtained
by investigation of the cytotoxic and biochemical ef-
fects of the new conjugate in prostate cancer cells.
We observed inhibition of cell growth and rapid in-duction of apoptosis in LNCaP cells that are resistant
to other chemotherapeutics that act through damage
to DNA. Cells treated with 11-dichloro showed a spe-
cific pattern of activation of cell-cycle checkpoint pro-
teins that was not observed with other DNA-damag-
ing agents or with a combination of the steroid and
alkylator portions of the molecule. Importantly, 11-
dichloro blocked the growth of LNCaP xenograft
tumors in immunocompromised mice. Our results
suggest that stable conjugates that can form adduct-
protein complexes in DNA have unique cytotoxic
mechanisms that may be useful in treating cancers.
Experimental Procedures
Chemical Synthesis
The bifunctional compounds used in these studies were chemically
synthesized in our laboratory. Details of the synthetic steps and
characterization of the final compounds by NRM and mass spec-
trometry are contained in Supplemental Data.
Reaction of 11 Compounds with DNA
The self-complementary oligonucleotide 5#-d(ATTATTGGCCAAT
AT)-3# was obtained from IDT DNA (Coralville, IA) and was purified
by denaturing PAGE. The oligonucleotide was 5# end labeled with
[γ-32P]ATP and allowed to react with test compounds at 37°C for 4
hr. The adducted oligonucleotide was treated with 1 M piperidine
for 1 hr at 90°C, and fragments were resolved by denaturing PAGE
to determine sites of modification. Reaction products were visual-
ized and quantified by PhosphorImager analysis. The calculated
percent cleavage is the proportion of radioactivity in the fragments
divided by the total and represents the extent of covalent modifica-
tion by the test compound.
Relative Affinity of 11-Compounds for Steroid Receptors
The relative binding affinities (RBA) of 11β compounds for the AR
and PR were assessed by a competitive binding assay. Whole-cell
extracts prepared from LNCaP and T47D cells were used as
sources of the AR and PR, respectively. RBAs were determined by
addition of increasing amounts of unlabeled test compounds to cell
extracts in the presence of radiolabeled ligands ([3H]-R1881, 83.5
Ci/mmol, or [3H]-progesterone 103.0 Ci/mmol; NEN, Boston, MA).
The amount of radiolabeled ligand that remained bound to protein
after removal of free ligand by adsorption to dextran-charcoal was
determined by scintillation counting [4].
Relative Affinity of 11-DNA Adducts for the AR and PR
We used an identical competitive binding assay to investigate the
ability of 11β-DNA adducts to bind to the AR and PR. In this case,
we used as competitor the covalently modified 16-mer deoxyoligo-
nucleotide prepared as described above. After reaction with 11β-
dichloro, unreacted compound was removed from the modified 16-
mer via three consecutive ethanol precipitations. We confirmed the
absence of unreacted 11β-dichloro and estimated the concentra-
tion of covalent adducts in the DNA by conducting a parallel exper-
iment with [14C]-11β (synthesized in our laboratory; details to be
published). Increasing amounts of modified or unreacted DNA were
added to cell extracts in the presence of radiolabeled ligands. After
incubation, unbound ligand was removed and the amount remain-
ing bound to the receptor determined as described above.
Cell Culture
Cell lines were obtained from the American Type Culture Collection
(ATCC, Rockville, MD). The LNCaP cell line was maintained in RPMI
1640 supplemented with 2.5 mg/ml glucose, 10% fetal bovine se-
rum (FBS; Hyclone, Salt Lake City, UT), 2 mM glutamax, 1 mM so-
dium pyruvate, and 100 mM HEPES. The T47D line was maintained
in MEM-α medium containing 10% FBS (Hyclone, Logan, UT), 0.1
mM nonessential amino acids, 100 mM HEPES, 2 g/ml bovine
insulin, and 1 ng/ml human epidermal growth factor (Invitrogen,
Carlsbad, CA). Cells were grown in a humidified 5% CO /air atmo-2
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786sphere at 37°C. For studies of cell morphology, LNCaP cells were n
sgrown on 13 mm diameter Nunc Thermanox cover slips coated
with poly-L-lysine (Invitrogen). At indicated time after treatment, f
mcells were washed twice in PBS, fixed in methanol, air dried, and
stained with Giemsa. c
s
wCell-Cycle Analysis
mCells in exponential growth were treated with test compounds dis-
ssolved in DMSO. At the indicated times, drug-containing media
pwas removed and detached cells were collected by centrifugation.
bAttached cells were harvested by trypsinization, pooled with re-
acovered detached cells, and washed once in PBS. Cells were fixed
tin 70% ethanol and stored at 4°C. For flow cytometry, cells were
hresuspended in 0.5 ml of a PBS solution containing 0.1% Triton
X-100, 0.2 mg/ml DNase-free RNase, and 0.02 mg/ml propidium
iodide (Sigma, St. Louis, MO). Cells were analyzed with a Becton
SDickinson FACScan flow cytometer with Cell Quest software (MIT
SFlow Cytometry Core Facility). Data were analyzed with ModFitLT
a2.0 software.
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Annexin V Staining and Analysis
ALNCaP cells in exponential growth were treated with test com-
pounds as described for cell-cycle analysis. At indicated times,
Tcells were trypsinized, washed with PBS, and stained with Annexin
DV-PE and 7-amino-actinomycin D according to manufacturer’s pro-
Mtocols (BD Pharmigen, San Diego, CA). Stained cells were analyzed
fby flow cytometery.
p
CDNA Isolation and Gel Electrophoresis
NAdherent cells were scraped directly into growth media and col-
Rlected along with any detached cells by centrifugation at 0°C. Cells
twere lysed in a solution containing 50 mM Tris (pH 8.0), 100 M
oEDTA, 0.5 mg/ml proteinase K, and 0.5% sodium lauryl sulfate. Af-
ter incubation at 50°C for 3 hr, the lysates were extracted once
with phenol chloroform, and nucleic acids were precipitated with R
ethanol and dissolved in TE (pH 7.5). RNA was digested with R
DNase-free RNase (Roche Biochemicals, Indianapolis, IN), and the A
solution was extracted once again with phenol chloroform. DNA P
was then isolated by ethanol precipitation, and the quantity re-
covered determined by O.D. 260 nm. Equal amounts of DNA from R
each sample were loaded onto a 1.5% agarose gel containing 0.1
g/ml ethidium bromide and resolved by electrophoresis. DNA was
visualized with a UV transilluminator.
Immunoblot Analysis
After exposure to various compounds for indicated times, LNCaP
cells were harvested in medium by scraping, washed once in PBS,
and suspended in 50 mM Tris (pH 7.5), 150 mM NaCl, 1 mM EDTA,
1% NP40, 0.5% Na-deoxychloate, 1 mM Na3VO4, 1 mM NaF, and
protease inhibitor cocktail (P8340; Sigma, St. Louis, MO) at 0°C.
The cell lysate was centrifuged at 14,000 × g for 10 min, and super-
natants were collected for analysis. Protein concentrations were
determined by the Bradford dye binding assay (Bio-Rad Laborato-
ries, Hercules, CA). Lysates were combined with SDS-PAGE sample
buffer (0.3 M Tris [pH 6.8], 2% SDS, 1% 2-mercaptoethanol, 10%
glycerol), and equal amounts of protein were resolved by SDS-
PAGE, followed by transfer to Immobilon-P membranes (Millipore,
Bedford, MA). Membranes were blocked with 5% nonfat milk in
Tris-buffered saline (0.1% Tween 20, 10 mM Tris [pH 7.4], 150 mM
NaCl) and probed with antibody against the protein of interest. An-
tibody complexes formed with horseradish peroxidase-conjugated
secondary antibodies were visualized by chemiluminescence (Su-
persignal West; Pierce, Rockford, IL). Antibodies were as follows:
PARP (06-557; Upstate Biotechnology, Lake Placid, NY), p27 Kip1
(2552; Cell Signaling Technologies, Beverly, MA), p21 (sc-397;
Santa Cruz Biotechnology, Santa Cruz, CA), and p45 Skp2 (32-
3300; Zymed Laboratotries, South San Francisco, CA).
Animal Studies
4- to 6-week-old NIH Swiss nu/nu athymic male mice (25 gm) were
obtained from the National Cancer Institute-Frederick Cancer Cen-
ter (Frederick, MD). Experiments were carried out under guidelines
of the MIT Animal Care Committee. Animals were injected subcuta-eously in the right flank with 5 × 106 LNCaP cells suspended in a
olution of 50% PBS/50% Matrigel (Collaborative Research, Bed-
ord, MA). Therapy commenced when a palpable tumor of approxi-
ately 4 × 4 mm formed (n = 5 per treatment group). The 11β-dichloro
ompound was dissolved in a vehicle composed of cremophor EL,
aline, and ethanol (43:30:27). Tumor dimensions were measured
ith vernier calipers. Tumor volumes were calculated with the for-
ula: π/6 × larger diameter × (smaller diameter)2. Statistical analy-
es were performed with a paired t test. At the end of the study
eriod, animals were euthanized with CO2. At the time of sacrifice,
lood samples were taken from several animals in each group for
complete blood count, along with serum chemistry and liver func-
ion analyses. A complete necropsy was also performed, including
istopathology on two animals from each group.
upplemental Data
upplemental Data include four figures and can be found with this
rticle online at http://www.chembiol.com/cgi/content/full/12/7/
79/DC1/.
cknowledgments
his work has been supported by Idea Development Award
AMD17-03-01-0085 from the U.S. Army Medical Research and
ateriel Command Prostate Cancer Research Program, a grant
rom the National Institutes of Health RO1 CA 77743-06, and a
ostdoctoral Fellowship from the Natural Sciences and Research
ouncil of Canada PDF-242490-2001 (A.N.D.). We also thank the
ational Institutes of Health for support of the Nuclear Magnetic
esonance facility (1S10RR13866-01) and the Massachusetts Insti-
ute of Technology Biological Engineering Mass Spectrometry Lab-
ratory for the use of their instruments.
eceived: March 11, 2005
evised: April 28, 2005
ccepted: May 4, 2005
ublished: July 22, 2005
eferences
1. DeVita, V.T. (1997). Principles of cancer management: chemo-
therapy. In Cancer: Principles and Practice of Oncology, V.T.
DeVita, S. Hellman, and S.A. Rosenberg, eds. (New York: Lip-
pincott-Raven), pp. 333–348.
2. Hurley, L.H. (2002). DNA and its associated processes as tar-
gets for cancer therapy. Nat. Rev. Cancer 2, 188–200.
3. Masters, J.R., and Koberle, B. (2003). Curing metastatic can-
cer: lessons from testicular germ-cell tumours. Nat. Rev. Can-
cer 3, 517–525.
4. Rink, S.M., Yarema, K.J., Solomon, M.S., Paige, L.A., Tadayoni-
Rebek, B.M., Essigmann, J.M., and Croy, R.G. (1996). Synthesis
and biological activity of DNA damaging agents that form de-
coy binding sites for the estrogen receptor. Proc. Natl. Acad.
Sci. USA 93, 15063–15068.
5. Mitra, K., Marquis, J.C., Hillier, S.M., Rye, P.T., Zayas, B., Lee,
A.S., Essigmann, J.M., and Croy, R.G. (2002). A rationally de-
signed genotoxin that selectively destroys estrogen receptor-
positive breast cancer cells. J. Am. Chem. Soc. 124, 1862–
1863.
6. Sharma, U., Marquis, J.C., Nicole, D.A., Hillier, S.M., Fedeles,
B., Rye, P.T., Essigmann, J.M., and Croy, R.G. (2004). Design,
synthesis, and evaluation of estradiol-linked genotoxicants as
anti-cancer agents. Bioorg. Med. Chem. Lett. 14, 3829–3833.
7. Heinlein, C.A., and Chang, C. (2004). Androgen receptor in
prostate cancer. Endocr. Rev. 25, 276–308.
8. Ruizeveld de Winter, J.A., Janssen, P.J., Sleddens, H.M., Ver-
leun-Mooijman, M.C., Trapman, J., Brinkmann, A.O., Santerse,
A.B., Schroder, F.H., and van der Kwast, T.H. (1994). Androgen
receptor status in localized and locally progressive hormone
refractory human prostate cancer. Am. J. Pathol. 144, 735–746.
9. Buchanan, G., Irvine, R.A., Coetzee, G.A., and Tilley, W.D.
(2001). Contribution of the androgen receptor to prostate can-
Bifunctional DNA-Damaging Anticancer Compound
787cer predisposition and progression. Cancer Metastasis Rev. 20,
207–223.
10. Heinlein, C.A., and Chang, C. (2002). Androgen receptor (AR)
coregulators: an overview. Endocr. Rev. 23, 175–200.
11. Fuhrmann, U., Hess-Stumpp, H., Cleve, A., Neef, G., Schwede,
W., Hoffmann, J., Fritzemeier, K.H., and Chwalisz, K. (2000).
Synthesis and biological activity of a novel, highly potent pro-
gesterone receptor antagonist. J. Med. Chem. 43, 5010–5016.
12. Napolitano, E., Fiaschi, R., and Hanson, R.N. (1990). Epoxida-
tion of estra-5(10),9(11)-dien derivatives; a convenient synthe-
sis of 11β-vinylestrone acetate. Gazz. Chim. Ital. 120, 323–326.
13. Teutsch, G., and Bêlanger, A. (1979). Regio and stereospecific
synthesis of 11β substituted norsteroids. Tetrahedron Lett. 22,
2051–2054.
14. Zhao, X.Y., Boyle, B., Krishnan, A.V., Navone, N.M., Peehl, D.M.,
and Feldman, D. (1999). Two mutations identified in the andro-
gen receptor of the new human prostate cancer cell line MDA
PCa 2a. J. Urol. 162, 2192–2199.
15. Povirk, L.F., and Shuker, D.E. (1994). DNA damage and muta-
genesis induced by nitrogen mustards. Mutat. Res. 318, 205–
226.
16. Chan, A., Reiter, R., Wiese, S., Fertig, G., and Gold, R. (1998).
Plasma membrane phospholipid asymmetry precedes DNA
fragmentation in different apoptotic cell models. Histochem.
Cell Biol. 110, 553–558.
17. Gorczyca, W., Bigman, K., Mittelman, A., Ahmed, T., Gong, J.,
Melamed, M.R., and Darzynkiewicz, Z. (1993). Induction of DNA
strand breaks associated with apoptosis during treatment of
leukemias. Leukemia 7, 659–670.
18. Kaufmann, S.H., Desnoyers, S., Ottaviano, Y., Davidson, N.E.,
and Poirier, G.G. (1993). Specific proteolytic cleavage of poly-
(ADP-ribose) polymerase: an early marker of chemotherapy-
induced apoptosis. Cancer Res. 53, 3976–3985.
19. Carrano, A.C., Eytan, E., Hershko, A., and Pagano, M. (1999).
SKP2 is required for ubiquitin-mediated degradation of the
CDK inhibitor p27. Nat. Cell Biol. 1, 193–199.
20. Lu, L., Schulz, H., and Wolf, D.A. (2002). The F-box protein
SKP2 mediates androgen control of p27 stability in LNCaP hu-
man prostate cancer cells. BMC Cell Biol. 3, 22.
21. Brix, H.P., Berger, M.R., Schneider, M.R., Tang, W.C., and
Eisenbrand, G. (1990). Androgen-linked alkylating agents: bio-
logical activity in methylnitrosourea-induced rat mammary car-
cinoma. J. Cancer Res. Clin. Oncol. 116, 538–549.
22. Eisenbrand, G., Berger, M.R., Brix, H.P., Fischer, J.E., Muhl-
bauer, K., Nowrousian, M.R., Przybilski, M., Schneider, M.R.,
Stahl, W., and Tang, W. (1989). Nitrosoureas. Modes of action
and perspectives in the use of hormone receptor affinity carrier
molecules. Acta Oncol. 28, 203–211.
23. Knebel, N., and von Angerer, E. (1988). Platinum complexes
with binding affinity for the estrogen receptor. J. Med. Chem.
31, 1675–1679.
24. Fredholm, B., Gunnarsson, K., Jensen, G., and Muntzing, J.
(1978). Mammary tumour inhibition and subacute toxicity in
rats of prednimustine and of its molecular components chlor-
ambucil and prednisolone. Acta Pharmacol. Toxicol. (Copenh.)
42, 159–163.
25. Kubota, T., Koh, J., Yamada, Y., Oka, S., Enomoto, K., Ishibiki,
K., Abe, O., Masui, O., and Asano, K. (1988). Mode of action of
estra-1,3,5(10)-triene-3,17 beta-diol 3-benzoate 17-[4-(4-bis(2-
chloroethyl)amino)phenyl)-1-oxobutoxy)acet ate) on human
breast carcinoma xenografts in nude mice. Jpn. J. Cancer Res.
79, 1224–1229.
26. Sack, J.S., Kish, K.F., Wang, C., Attar, R.M., Kiefer, S.E., An, Y.,
Wu, G.Y., Scheffler, J.E., Salvati, M.E., Krystek, S.R., Jr., et al.
(2001). Crystallographic structures of the ligand-binding do-
mains of the androgen receptor and its T877A mutant com-
plexed with the natural agonist dihydrotestosterone. Proc.
Natl. Acad. Sci. USA 98, 4904–4909.
27. Berrevoets, C.A., Umar, A., and Brinkmann, A.O. (2002). Antian-
drogens: selective androgen receptor modulators. Mol. Cell.
Endocrinol. 198, 97–103.
28. Veldscholte, J., Berrevoets, C.A., Ris-Stalpers, C., Kuiper, G.G.,
Jenster, G., Trapman, J., Brinkmann, A.O., and Mulder, E.
(1992). The androgen receptor in LNCaP cells contains a muta-tion in the ligand binding domain which affects steroid binding
characteristics and response to antiandrogens. J. Steroid Bio-
chem. Mol. Biol. 41, 665–669.
29. McDonald, S., Brive, L., Agus, D.B., Scher, H.I., and Ely, K.R.
(2000). Ligand responsiveness in human prostate cancer:
structural analysis of mutant androgen receptors from LNCaP
and CWR22 tumors. Cancer Res. 60, 2317–2322.
30. Taplin, M.E., Bubley, G.J., Ko, Y.J., Small, E.J., Upton, M.,
Rajeshkumar, B., and Balk, S.P. (1999). Selection for androgen
receptor mutations in prostate cancers treated with androgen
antagonist. Cancer Res. 59, 2511–2515.
31. Sherr, C.J., and Roberts, J.M. (1995). Inhibitors of mammalian
G1 cyclin-dependent kinases. Genes Dev. 9, 1149–1163.
32. Kim, I.Y., Kim, J.H., Zelner, D.J., Ahn, H.J., Sensibar, J.A., and
Lee, C. (1996). Transforming growth factor-beta1 is a mediator
of androgen-regulated growth arrest in an androgen-respon-
sive prostatic cancer cell line, LNCaP. Endocrinology 137,
991–999.
33. Lee, C., Sutkowski, D.M., Sensibar, J.A., Zelner, D., Kim, I., Am-
sel, I., Shaw, N., Prins, G.S., and Kozlowski, J.M. (1995). Regu-
lation of proliferation and production of prostate-specific anti-
gen in androgen-sensitive prostatic cancer cells, LNCaP, by
dihydrotestosterone. Endocrinology 136, 796–803.
34. Tsihlias, J., Zhang, W., Bhattacharya, N., Flanagan, M., Klotz,
L., and Slingerland, J. (2000). Involvement of p27Kip1 in G1
arrest by high dose 5 alpha-dihydrotestosterone in LNCaP hu-
man prostate cancer cells. Oncogene 19, 670–679.
35. Spruck, C., Strohmaier, H., Watson, M., Smith, A.P., Ryan, A.,
Krek, T.W., and Reed, S.I. (2001). A CDK-independent function
of mammalian Cks1: targeting of SCF(Skp2) to the CDK inhibi-
tor p27Kip1. Mol. Cell 7, 639–650.
36. Ganoth, D., Bornstein, G., Ko, T.K., Larsen, B., Tyers, M., Pa-
gano, M., and Hershko, A. (2001). The cell-cycle regulatory pro-
tein Cks1 is required for SCF(Skp2)-mediated ubiquitinylation
of p27. Nat. Cell Biol. 3, 321–324.
37. Bashir, T., Dorrello, N.V., Amador, V., Guardavaccaro, D., and
Pagano, M. (2004). Control of the SCF(Skp2-Cks1) ubiquitin li-
gase by the APC/C(Cdh1) ubiquitin ligase. Nature 428, 190–
193.
38. Sudo, T., Ota, Y., Kotani, S., Nakao, M., Takami, Y., Takeda,
S., and Saya, H. (2001). Activation of Cdh1-dependent APC is
required for G1 cell cycle arrest and DNA damage-induced G2
checkpoint in vertebrate cells. EMBO J. 20, 6499–6508.
39. Gartel, A.L., and Tyner, A.L. (2002). The role of the cyclin-
dependent kinase inhibitor p21 in apoptosis. Mol. Cancer Ther.
1, 639–649.
40. Isaacs, W.B., Carter, B.S., and Ewing, C.M. (1991). Wild-type
p53 suppresses growth of human prostate cancer cells con-
taining mutant p53 alleles. Cancer Res. 51, 4716–4720.
41. el-Deiry, W.S., Tokino, T., Velculescu, V.E., Levy, D.B., Parsons,
R., Trent, J.M., Lin, D., Mercer, W.E., Kinzler, K.W., and Vo-
gelstein, B. (1993). WAF1, a potential mediator of p53 tumor
suppression. Cell 75, 817–825.
42. Martinez, L.A., Yang, J., Vazquez, E.S., Rodriguez-Vargas,
M.C., Olive, M., Hsieh, J.T., Logothetis, C.J., and Navone, N.M.
(2002). p21 modulates threshold of apoptosis induced by DNA-
damage and growth factor withdrawal in prostate cancer cells.
Carcinogenesis 23, 1289–1296.
43. Waga, S., and Stillman, B. (1998). Cyclin-dependent kinase in-
hibitor p21 modulates the DNA primer-template recognition
complex. Mol. Cell. Biol. 18, 4177–4187.
